Skip to main content
    I

    Iradimed Co (IRMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $84.84
    -0.51 (-0.60%)

    Market Cap: $1.09B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Iradimed Co (IRMD) Financials: Revenue, Profit and Cash Flow

    Updated Oct 30, 2026. Financial statements from company filings, amounts in US dollars.

    Iradimed reported revenue of $83.81M for the fiscal year ended Dec 31, 2025, up 14.4% from the year before. That year, net income was $22.48M with a net margin of 26.8%, operating cash flow was $24.95M and free cash flow was $16.53M. The quarter ended Sep 30, 2026 had revenue of $24.20M and net income of $6.51M.

    Revenue and Margins

    The operating margin was 31.2% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $32.50M, a compound annual rate of 11.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$83.81M+14.4%76.7%31.2%26.8%
    Dec 2024$73.24M+11.7%76.9%30.0%26.3%
    Dec 2023$65.56M+23.0%76.5%30.6%26.2%
    Dec 2022$53.30M+27.5%77.4%29.3%24.1%
    Dec 2021$41.81M+31.8%76.6%23.5%22.3%
    Dec 2020$31.72M-17.7%74.3%-2.4%4.3%
    Dec 2019$38.52M+26.5%77.1%22.5%25.0%
    Dec 2018$30.44M+31.9%76.3%19.7%20.7%
    Dec 2017$23.08M-29.0%75.9%5.6%2.2%
    Dec 2016$32.50MN/A81.1%33.6%22.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 16.9% from the year before. In the quarter ended Sep 2026, net income rose 16.7% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$83.81M$73.24M$65.56M$53.30M$41.81M$31.72M$38.52M$30.44M$23.08M$32.50M
    Cost of revenue$19.49M$16.89M$15.40M$12.02M$9.76M$8.14M$8.82M$7.21M$5.57M$6.15M
    Gross profit$64.32M$56.35M$50.16M$41.28M$32.05M$23.57M$29.70M$23.23M$17.51M$26.34M
    Research and development$2.98M$2.83M$2.86M$2.28M$1.91M$1.90M$1.43M$1.52M$1.72M$1.35M
    Operating income$26.15M$21.96M$20.04M$15.63M$9.82M-$756.09K$8.65M$6.00M$1.29M$10.92M
    Net income$22.48M$19.23M$17.19M$12.83M$9.33M$1.37M$9.63M$6.30M$499.76K$7.21M
    EBITDA$29.53M$25.09M$22.50M$16.85M$11.24M$721.95K$10.29M$7.30M$2.71M$11.91M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$24.20M$20.47M$21.98M$22.69M$21.20M$20.41M$19.51M$19.39M$18.33M$17.93M$17.60M$17.45M
    Gross profit$18.46M$15.16M$16.81M$17.03M$16.49M$15.96M$14.84M$14.76M$14.19M$14.01M$13.39M$13.41M
    Operating income$8.14M$6.39M$7.24M$7.09M$6.83M$6.79M$5.43M$5.80M$5.79M$5.63M$4.75M$5.16M
    Net income$6.51M$5.22M$5.82M$6.44M$5.58M$5.77M$4.69M$5.15M$5.05M$4.90M$4.14M$4.54M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $51.16M were 47.0% of total assets of $108.78M, against total liabilities of $14.16M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$108.78M$98.33M$92.16M$85.51M$82.88M$71.07M$66.73M$48.44M$39.01M$37.19M
    Current assets$81.20M$75.24M$76.00M$77.49M$76.24M$63.74M$58.96M$44.54M$35.11M$33.86M
    Cash and equivalents$51.16M$52.23M$49.76M$57.96M$62.00M$50.07M$43.48M$28.03M$18.21M$17.71M
    Total liabilities$14.16M$11.51M$20.74M$11.84M$10.71M$9.68M$11.20M$6.50M$6.08M$5.31M
    Short-term debtN/A$153.26K$427.96K$293.47K$276.57K$255.70K$240.84K$133.00K$1.70M$1.39M
    Shareholder equity$94.62M$86.82M$71.42M$73.67M$72.17M$61.38M$55.52M$41.95M$32.93M$31.89M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$121.07M$114.97M$114.39M$108.78M$114.72M$106.45M$101.73M$98.33M$94.25M$89.95M$88.01M$92.16M
    Total liabilities$14.62M$13.23M$15.88M$14.16M$16.37M$12.15M$11.68M$11.51M$10.81M$10.28M$11.89M$20.74M
    Cash and equivalents$63.29M$59.08M$56.37M$51.16M$56.53M$53.00M$50.33M$52.23M$51.72M$48.54M$45.13M$49.76M
    Shareholder equity$106.45M$101.75M$98.51M$94.62M$98.35M$94.30M$90.05M$86.82M$83.43M$79.67M$76.12M$71.42M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 66.3% of operating cash flow. Dividends came to 91.0% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$24.95M$25.62M$13.47M$10.04M$11.26M$5.82M$10.23M$7.38M$3.42M$9.41M
    Capital expenditures$8.42M$8.82M$8.01M$1.87M$741.76K$636.75K$485.81K$264.67K$824.76K$1.52M
    Free cash flow$16.53M$16.81M$5.46M$8.17M$10.52M$5.18M$9.75M$7.11M$2.59M$7.88M
    Dividends paid$15.04M$13.68M$13.22M$12.56M$0$12.56M$12.56MN/A$0$0
    Share repurchasesN/AN/AN/AN/AN/AN/AN/AN/A$1.82M$9.97M
    Investing cash flow-$8.42M-$8.82M-$8.01M-$1.37M$648.24K$246.97K$3.20M$1.52M-$1.02M-$1.94M
    Financing cash flow-$17.60M-$14.34M-$13.66M-$12.71M$24.43K$522.48K$2.02M$929.87K-$1.90M-$9.12M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$7.00M$5.94M$8.29M$5.92M$6.99M$7.75M$4.29M$5.99M$9.12M$6.64M$3.88M$3.91M
    Capital expenditures$130.00K$185.00K$403.00K$416.41K$1.14M$2.64M$3.70M$3.06M$4.01M$1.27M$478.80K$632.82K
    Free cash flow$6.87M$5.75M$7.89M$5.51M$5.85M$5.11M$595.00K$2.93M$5.10M$5.37M$3.40M$3.28M
    Last 12 quarters

    Frequently Asked Questions About IRMD

    What is Iradimed's annual revenue?

    Iradimed reported revenue of $83.81M for the fiscal year ended Dec 31, 2025.

    How fast is Iradimed's revenue growing?

    Revenue was up 14.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 16.3%.

    Is Iradimed profitable?

    Yes. Iradimed reported net income of $22.48M for the fiscal year ended Dec 31, 2025, with a net margin of 26.8%.

    How much free cash flow does IRMD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $24.95M minus capital expenditures of $8.42M produced free cash flow of $16.53M.

    How much debt does Iradimed have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $51.16M.